Skip to main content

Advertisement

Log in

Does angiotensin receptor blockade improve outcomes in patients with heart failure and preserved ejection fraction? Results of the I-PRESERVE study

  • Clinical Trials Report
  • Published:
Current Heart Failure Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Redfield MM, Jacobsen SJ, Burnett JC Jr, et al.: Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003, 289:194–202.

    Article  PubMed  Google Scholar 

  2. Gottdiener JS, McClelland RL, Marshall R, et al.: Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study. Ann Intern Med 2002, 137:631–639.

    PubMed  Google Scholar 

  3. Senni M, Redfield MM: Heart failure with preserved systolic function. A different natural history? J Am Coll Cardiol 2001, 38:1277–1282.

    Article  PubMed  CAS  Google Scholar 

  4. Bernal J, Pitta SR, Thatai D: Role of the renin-angiotensin-aldosterone system in diastolic heart failure: potential for pharmacologic intervention. Am J Cardiovasc Drugs 2006, 6:373–381.

    Article  PubMed  CAS  Google Scholar 

  5. Cleland JG, Tendera M, Adamus J, et al.: The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006, 27:2338–2345.

    Article  PubMed  CAS  Google Scholar 

  6. Yusuf S, Pfeffer MA, Swedberg K, et al.: Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003, 362:777–781.

    Article  PubMed  CAS  Google Scholar 

  7. Carson P, Massie BM, McKelvie R, et al.: The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. J Card Fail 2005, 11:576–585.

    Article  PubMed  CAS  Google Scholar 

  8. McMurray JJ, Carson PE, Komajda M, et al.: Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. Eur J Heart Fail 2008, 10:149–156.

    Article  PubMed  Google Scholar 

  9. National Heart, Lung, and Blood Institute: Aldosterone antagonist therapy for adults with heart failure and preserved systolic function (TOPCAT). Available at http://clinicaltrials.gov/ct2/show/NCT00094302?term=TOPCAT&rank=1. Accessed March 2009.

  10. Connelly K, Kelly DJ, Kim S, et al.: The direct renin inhibitor, aliskiren, improves cardiac function via direct renin inhibition and via renin receptor modulation in a rodent model of diabetic diastolic heart failure [abstract]. Circulation 2008, 118(Suppl 2):S1166.

    Google Scholar 

  11. Krum H, Connelly K, Zhang M, et al.: Directly targeting myocardial fibrosis with FT-011 improves cardiac remodelling in experimental diabetic cardiomyopathy [abstract]. Circulation 2008, 118(Suppl 2):S283.

    Google Scholar 

  12. Little WC, Zile MR, Kitzman DW, et al.: The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail 2005, 11:191–195.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Krum, H. Does angiotensin receptor blockade improve outcomes in patients with heart failure and preserved ejection fraction? Results of the I-PRESERVE study. Curr Heart Fail Rep 6, 65–67 (2009). https://doi.org/10.1007/s11897-009-0011-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11897-009-0011-y

Keywords

Navigation